HASC2011corpus: Towards the Common Ground of Human Activity Recognition

UbiComp '11 Proceedings of the 13th international conference on Ubiquitous computing, September 17-21, 2011, Beijing, ChinaHuman activity recognition through the wearable sensor will enable a next-generation human-oriented biquitous computing. However, most of research on human activity recognition so far is based on small number of subjects, and non-public data. To overcome the situation, we have gathered 4897 accelerometer data with 116 subjects and compose them as HASC2011corpus. In the field of pattern recognition, it is very important to evaluate and to improve the recognition methods by using the same dataset as a common ground. We make the HASC2011corpus into public for the research community to use it as a common ground of the Human Activity Recognition. We also show several facts and results of obtained from the corpus

HASC2011corpus: Towards the Common Ground of Human Activity Recognition

Human activity recognition through the wearable sensor will enable a next-generation human-oriented biquitous computing. However, most of research on human activity recognition so far is based on small number of subjects, and non-public data. To overcome the situation, we have gathered 4897 accelerometer data with 116 subjects and compose them as HASC2011corpus. In the field of pattern recognition, it is very important to evaluate and to improve the recognition methods by using the same dataset as a common ground. We make the HASC2011corpus into public for the research community to use it as a common ground of the Human Activity Recognition. We also show several facts and results of obtained from the corpus.UbiComp \u2711 Proceedings of the 13th international conference on Ubiquitous computing, September 17-21, 2011, Beijing, Chin

The establishment of the 'Writing Check System' using rubrics

4000000196大手前大学の学習支援センターでは、webフォームを用いて学生がライティングを送り、ルーブリックのかたちでフィードバックを得る「ライティング・チェック・システム」を実施している。本論では当該システム導入の経緯からその運用、また使用しているルーブリックを紹介する。ライティングへの学習アドバイスは、対面で行うほうがより高い学習効果を得られるだろうことは了解している。しかし学生のなかには、さまざまな理由から学習支援センターへの来室が困難な者がいる。本システムは、対面アドバイスが難しい学生であっても受けることができる学習支援の一例として位置づけたい。This is a report on the writing check system (WCS) at the learning support center of Otemae University during the past eighteen months. The procedure of WCS is as follows: 1) a student sends his/her writing through a web form (written in Japanese), 2) the learning support centre staff check the writing, 3) the staff returns the writing to the student by email. Following this procedure, rubrics are used for evaluation. The benefit of the WCS is that students are not required to actually visit the center, but can send their writing and receive advice on improving it.departmental bulletin pape

A Japanese retrospective study of non-tuberculous mycobacterial infection in children, adolescents, and young adult patients with hematologic-oncologic diseases

Non-tuberculous mycobacterial infection (NTM) is rare in healthy children, with lymphadenitis being the most common presentation. Immunocompromised populations are known to be at high risk, but the clinical picture of NTM infection in pediatric hematology/oncology patients is unclear. In this nationwide retrospective analysis of patients under the age of 40 treated in Japanese pediatric hematology/oncology departments who developed NTM infection between January 2010 and December 2020, 36 patients (21 patients with hematopoietic stem cell transplantation (HSCT) and 15 nontransplant patients) were identified. Post-transplant patients were infected with NTM at 24 sites, including the lungs (n = 12), skin and soft tissues (n = 6), bloodstream (n = 4), and others (n = 2). Nine of twelve patients with pulmonary NTM infection had a history of pulmonary graft-versus-host disease (GVHD), and rapid-growing mycobacteria (RGM) were isolated from five of them. In nontransplant patients, the primary diseases were acute lymphoblastic leukemia (ALL; n = 5), inborn errors of immunity (IEI; n = 6), and others (n = 4). All cases of ALL had bloodstream infections with RGM, whereas all cases of IEI were infected with slow-growing mycobacteria (SGM). In summary, three typical clinical scenarios for pediatric hematology/oncology patients have been established: RGM-induced pulmonary disease in patients with pulmonary GVHD, RGM bloodstream infection in patients with ALL, and SGM infection in patients with IEI. Our findings suggest that NTM must be regarded as a pathogen for infections in these high-risk patients, especially those with pulmonary GVHD, who may require active screening for NTM

入学前から一貫した学士課程教育のための導入教育プログラムの実践

4000000196大手前大学では、2000年代中盤からの大学教育改革において、多様な学生に対する教育の質保証のためのさまざまな取り組みのひとつとして、独自の導入教育プログラムを全学的に推進してきた。入学前から一貫した学士課程教育の導入部として、「学生の学び」を主眼とした明確なコンセプトにもとづく導入教育プログラムを志向し、その企画・運営プロセスにおいては多くの部署・教職員が連携してきた。数年にわたる試行錯誤を経て、学生に対する一定の成果が上がりつつあるほか、FD／SDとしての企画・運営という機能が生まれてきている。本稿では本導入教育プログラムに関連する背景や経緯、実施成果、マネジメント体制などについて、現場に携わってきた立場からまとめる。Otemae University has implemented an introductory education program through the whole university, which is one of quality assurance of education for students with high diversity. The university has aspired to make the program based on a clear concept of "students' learning" as the introductory part of the baccalaureate degree program consistent since pre-admission. Various teachers and staff have cooperated in the process of planning and the operation of the program. Through trial and error for several years, there have been some outcomes about the students, and the process of planning and operation has gradually been a kind of faculty development (FD) or staff development (SD). In this paper, we summarize the background, process, outcomes and management of the program from the position of the practitioner.departmental bulletin pape

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

PURPOSE Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially in pMMR disease. METHODS This phase III, global, double-blind, placebo-controlled trial randomly assigned eligible patients with newly diagnosed advanced or recurrent endometrial cancer 1:1:1 to: carboplatin/paclitaxel plus durvalumab placebo followed by placebo maintenance (control arm); carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib placebo (durvalumab arm); or carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib (durvalumab + olaparib arm). The primary end points were progression-free survival (PFS) in the durvalumab arm versus control and the durvalumab + olaparib arm versus control. RESULTS Seven hundred eighteen patients were randomly assigned. In the intention-to-treat population, statistically significant PFS benefit was observed in the durvalumab (hazard ratio [HR], 0.71 [95% CI, 0.57 to 0.89]; P = .003) and durvalumab + olaparib arms (HR, 0.55 [95% CI, 0.43 to 0.69]; P < .0001) versus control. Prespecified, exploratory subgroup analyses showed PFS benefit in dMMR (HR [durvalumab v control], 0.42 [95% CI, 0.22 to 0.80]; HR [durvalumab + olaparib v control], 0.41 [95% CI, 0.21 to 0.75]) and pMMR subgroups (HR [durvalumab v control], 0.77 [95% CI, 0.60 to 0.97]; HR [durvalumab + olaparib v control] 0.57; [95% CI, 0.44 to 0.73]); and in PD-L1-positive subgroups (HR [durvalumab v control], 0.63 [95% CI, 0.48 to 0.83]; HR [durvalumab + olaparib v control], 0.42 [95% CI, 0.31 to 0.57]). Interim overall survival results (maturity approximately 28%) were supportive of the primary outcomes (durvalumab v control: HR, 0.77 [95% CI, 0.56 to 1.07]; P = .120; durvalumab + olaparib v control: HR, 0.59 [95% CI, 0.42 to 0.83]; P = .003). The safety profiles of the experimental arms were generally consistent with individual agents. CONCLUSION Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab with or without olaparib demonstrated a statistically significant and clinically meaningful PFS benefit in patients with advanced or recurrent endometrial cancer